放射性核素标记的纳米探针在肿瘤多模态显像中的研究进展  

Advances in radionuclide-labelled nanoprobes for multimodal imaging of tumors

作　　者：岳建兰 林志春 Yue Jianlan;Lin Zhichun(Department of Nuclear Medicine,Characteristic Medical Center of Chinese People′s Armed Police Forces,Tianjin 300162,China)

机构地区：[1]武警特色医学中心核医学科,天津300162

出　　处：《国际放射医学核医学杂志》2024年第5期323-329,共7页International Journal of Radiation Medicine and Nuclear Medicine

摘　　要：早期诊断和治疗对提高恶性肿瘤患者的治愈率和生存率至关重要。近年来,多模态分子影像的发展为恶性肿瘤的早期诊断和治疗提供了新的方向。核医学显像具有高灵敏度、高组织穿透性及精确定量的优势,在疾病诊断和病情监测中发挥着重要作用,将其与CT、MRI、光学显像等多种显像方式相结合,能为肿瘤的诊疗提供更加全面的解剖及生物代谢信息。目前,基于纳米医学策略构建放射性核素标记的多模态探针已受到普遍关注,笔者结合国内外相关临床前研究结果,对放射性核素标记的纳米探针在肿瘤多模态显像中的研究进展进行综述。Early diagnosis and treatment are crucial for improving the cure rate and survival rate of patients with malignant tumors.In recent years,the development of multimodal molecular imaging has provided new directions for the early diagnosis and treatment of malignant tumors.Nuclear medicine imaging has the advantages of high sensitivity,high tissue penetration,and precise quantification,which can play an important role in disease diagnosis and monitoring.Combining it with CT,MRI,optical imaging and other imaging modalities,can provide more comprehensive anatomical and biometabolic information for the diagnosis and treatment of tumors.Currently,the construction of radionuclide-labelled multimodal probes based on nanomedicine strategies has received widespread attention.The authors review the research progress on radionuclide-labelled nanoprobes in multimodal imaging of tumors based on relevant preclinical research results at home and abroad.

关 键 词：放射性同位素 纳米探针 多模态显像 肿瘤诊断 

分 类 号：R730.44[医药卫生—肿瘤]